Paolillo (Merck): “Lavoriamo per offrire soluzioni per bisogni non soddisfatti dei pazienti ”

adnkronos

(Adnkronos) - Merck ha annunciato oggi che l'Agenzia italiana del farmaco ha ammesso alla rimborsabilità tepotinib, un nuovo farmaco per il trattamento dei pazienti adulti affetti da carcinoma polmonare non a piccole cellule (NSCLC) avanzato, con alterazioni genetiche che causano lo skipping dell’esone 14 del fattore di transizione mesenchimale epiteliale (METex14). A margine della conferenza stampa è intervenuto Andrea Paolillo, direttore medico di Merck Italia.

Transcript

00:00 (upbeat music)

00:02 (speaking in foreign language)

00:08 (speaking in foreign language)

00:12 (speaking in foreign language)

00:16 (speaking in foreign language)

00:21 (speaking in foreign language)

00:25 (speaking in foreign language)

00:29 (speaking in foreign language)

00:33 (speaking in foreign language)

00:37 (speaking in foreign language)

00:41 (speaking in foreign language)

00:44 (speaking in foreign language)

00:48 (speaking in foreign language)

00:52 (speaking in foreign language)

00:56 (speaking in foreign language)

01:00 (speaking in foreign language)

01:04 (speaking in foreign language)

01:08 (speaking in foreign language)

01:12 (speaking in foreign language)

01:17 (speaking in foreign language)

01:20 (speaking in foreign language)

01:24 (speaking in foreign language)

01:28 (speaking in foreign language)

01:32 (speaking in foreign language)

01:36 (speaking in foreign language)

01:40 (speaking in foreign language)

01:44 (speaking in foreign language)

01:48 (speaking in foreign language)

01:52 the growth factor, this is its evolution.

Category

Transcript

Comments

Recommended